🍽️ Blautia wexlerae {Blautia wexlerae}

AI Engines For more Details: PerplexityKagi LabsYou

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

Data Contradictions β€” Limits of Certainity

Impacted of Blautia wexlerae {Blautia wexlerae} On Probiotics

Rank Probitoic Impact
species Akkermansia muciniphila Increases

Bacteria Impacted by Blautia wexlerae {Blautia wexlerae}

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Increases 👪 Source Study
Rikenellaceae family Increases 📓 Source Study
Acetobacteroides genus Increases 👶 Source Study
Anaerocella genus Increases 👶 Source Study
Butyricicoccus genus Increases 👪 Source Study
Gallalistipes genus Increases 👶 Source Study
Millionella genus Increases 👶 Source Study
Mucinivorans genus Increases 👶 Source Study
Rikenella genus Increases 👶 Source Study
Ruminofilibacter genus Increases 👶 Source Study
Tidjanibacter genus Increases 👶 Source Study
Akkermansia genus Increases 📓 Source Study
Alistipes genus Increases 📓 Source Study High Levels linked to long-lived individuals
environmental samples no rank Increases 👶 Source Study
environmental samples no rank Increases 👶 Source Study
environmental samples no rank Increases 👶 Source Study
Rikenellaceae incertae sedis no rank Increases 👶 Source Study
unclassified Akkermansia no rank Increases 👶 Source Study
unclassified Alistipes no rank Increases 👶 Source Study
unclassified Rikenellaceae no rank Increases 👶 Source Study
Bacteroidales order Increases 👪 Source Study
Akkermansia glycaniphila species Increases 👶 Source Study
Alistipes megaguti species Increases 👶 Source Study
Alistipes indistinctus species Increases 👶 Source Study
Alistipes dispar species Increases 👶 Source Study
Alistipes ihumii species Increases 👶 Source Study
Akkermansia massiliensis species Increases 👶 Source Study
Alistipes hominis species Increases 👶 Source Study
Alistipes inops species Increases 👶 Source Study
Alistipes massiliensis species Increases 👶 Source Study
Alistipes montrealensis species Increases 👶 Source Study
Alistipes provencensis species Increases 👶 Source Study
Alistipes putredinis species Increases 👶 Source Study
Alistipes timonensis species Increases 👶 Source Study
Candidatus Akkermansia intestinavium species Increases 👶 Source Study
Candidatus Alistipes avistercoris species Increases 👶 Source Study
Candidatus Alistipes cottocaccae species Increases 👶 Source Study
Candidatus Alistipes excrementavium species Increases 👶 Source Study
Candidatus Alistipes excrementigallinarum species Increases 👶 Source Study
Candidatus Alistipes excrementipullorum species Increases 👶 Source Study
Candidatus Alistipes faecigallinarum species Increases 👶 Source Study
Candidatus Alistipes intestinigallinarum species Increases 👶 Source Study
Candidatus Alistipes merdavium species Increases 👶 Source Study
Candidatus Alistipes merdipullorum species Increases 👶 Source Study
Candidatus Alistipes pullicola species Increases 👶 Source Study
Candidatus Alistipes pullistercoris species Increases 👶 Source Study
Candidatus Alistipes stercorigallinarum species Increases 👶 Source Study
Candidatus Alistipes stercoripullorum species Increases 👶 Source Study
Alistipes senegalensis species Increases 👶 Source Study
Alistipes shahii species Increases 👶 Source Study
Alistipes communis species Increases 👶 Source Study
Alistipes finegoldii species Increases 👶 Source Study
Alistipes onderdonkii species Increases 👶 Source Study
Akkermansia muciniphila species Increases 👶 Source Study High Levels linked to long-lived individuals
Butyricicoccus faecihominis species Increases 📓 Source Study

Impact of Blautia wexlerae {Blautia wexlerae} on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.3 0.3
ADHD 1.2 -1.2
Allergic Rhinitis (Hay Fever) 0.6 0.3 1
Allergies 1.8 0.9 1
Allergy to milk products 0.6 -0.6
Alzheimer's disease 0.9 2 -1.22
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 1.2 -1
Ankylosing spondylitis 0.6 1.2 -1
Anorexia Nervosa 0.6 -0.6
Asthma 1.5 1.5
Atherosclerosis 0.9 0.9
Atrial fibrillation 0.9 0.6 0.5
Autism 2.6 2.4 0.08
Bipolar Disorder 0.9 -0.9
Brain Trauma 0.3 0.3
Carcinoma 0.6 0.6 0
Celiac Disease 1.2 1.2
Cerebral Palsy 0.6 -0.6
Chronic Fatigue Syndrome 0.9 -0.9
Chronic Kidney Disease 0.9 0.9
Chronic Urticaria (Hives) 0.6 0.6
Cognitive Function 1.5 0.6 1.5
Colorectal Cancer 0.9 3.3 -2.67
COVID-19 3 2.1 0.43
Crohn's Disease 1.9 1.5 0.27
deep vein thrombosis 0.3 0.6 -1
Depression 3.8 2.7 0.41
Eczema 0.3 -0.3
Endometriosis 0.3 0.3
Epilepsy 1.2 2.2 -0.83
erectile dysfunction 0.6 0.6
Fibromyalgia 0.3 1.1 -2.67
Functional constipation / chronic idiopathic constipation 0.4 1.2 -2
gallstone disease (gsd) 1.2 1.2
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.6 0.3 1
Generalized anxiety disorder 0.9 0.6 0.5
giant cell arteritis 0.3 -0.3
Gout 1.5 0.9 0.67
Graves' disease 1.2 0.3 3
Gulf War Syndrome 1.2 1.2
Hashimoto's thyroiditis 0.6 1.2 -1
Heart Failure 0.6 0.6
hemorrhagic stroke 0.6 0.6 0
hypercholesterolemia (High Cholesterol) 0.6 0.6
hyperglycemia 1.2 0.6 1
Hyperlipidemia (High Blood Fats) 0.9 0.6 0.5
hypertension (High Blood Pressure 1.8 2.1 -0.17
Hypothyroidism 0.3 0.6 -1
Hypoxia 0.9 -0.9
IgA nephropathy (IgAN) 0.9 0.9
Inflammatory Bowel Disease 2.1 1.2 0.75
Insomnia 1.2 0.3 3
Intracranial aneurysms 0.6 -0.6
Irritable Bowel Syndrome 2.4 2.1 0.14
ischemic stroke 1.2 -1.2
Juvenile idiopathic arthritis 0.6 -0.6
Liver Cirrhosis 2.7 1.5 0.8
Long COVID 2.4 0.6 3
Low bone mineral density 0.6 0.6
Lung Cancer 1 1
Lymphoma 0.6 0.6
Mast Cell Issues / mastitis 0.9 0.9
ME/CFS with IBS 0.6 -0.6
Menopause 0.6 0.6
Metabolic Syndrome 2.1 2.4 -0.14
Mood Disorders 3 3.6 -0.2
multiple chemical sensitivity [MCS] 0.6 -0.6
Multiple Sclerosis 0.3 2.2 -6.33
Multiple system atrophy (MSA) 1.6 -1.6
neuropathic pain 0.6 0.6
Neuropathy (all types) 0.6 -0.6
neuropsychiatric disorders (PANDAS, PANS) 0.6 -0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.4 0.6 3
NonCeliac Gluten Sensitivity 0.6 -0.6
Obesity 3.8 3.6 0.06
obsessive-compulsive disorder 0.6 0.6 0
Osteoarthritis 0.6 0.5 0.2
Osteoporosis 2.1 2.1
Parkinson's Disease 0.9 4.3 -3.78
Peanut Allergy 1.2 1.2
Polycystic ovary syndrome 2.1 0.6 2.5
Premenstrual dysphoric disorder 0.3 0.3
Psoriasis 1.5 0.6 1.5
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.6 0.9 -0.5
Schizophrenia 1.5 0.9 0.67
sensorineural hearing loss 0.6 -0.6
Sjögren syndrome 0.6 0.6 0
Sleep Apnea 1.2 1.2
Stress / posttraumatic stress disorder 0.6 0.6 0
Systemic Lupus Erythematosus 0.6 0.6
Tourette syndrome 0.6 -0.6
Type 1 Diabetes 0.3 1.2 -3
Type 2 Diabetes 2.1 1.8 0.17
Ulcerative colitis 2 1.2 0.67
Unhealthy Ageing 1.6 1.6
Vitiligo 0.9 0.9

BOOM

All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.

Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.


The awesome web hosting site that we use. Try it if you need to host (or unhappy with current provider)